Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31207939 | 0.82 | CYP1A2 (0.32) | MAPTSMN1; SMN2ALDH1A1CYP1A2KDM4E | |
| SCHEMBL179565 | 0.79 | CYP1A2 (0.50) | MAPTSMN1; SMN2ALDH1A1TSHRCYP1A2 | |
| SCHEMBL3012697 | 0.77 | MEN1 (0.30) | — | |
| SCHEMBL27781648 | 0.77 | GABRA1 (0.46) | MAPTSMN1; SMN2ALDH1A1TSHRCYP1A2 | |
| SCHEMBL27758156 | 0.77 | PRSS1 (0.55) | ALDH1A1TSHR | |
| SCHEMBL3015836 | 0.76 | ALDH1A1 (0.44) | MAPTSMN1; SMN2ALDH1A1TSHRCYP1A2 | |
| SCHEMBL3008544 | 0.74 | LMNA (0.54) | MAPTSMN1; SMN2ALDH1A1TSHRCYP1A2 | |
| SCHEMBL3014408 | 0.73 | CNR2 (0.32) | MAPTALDH1A1 | |
| SCHEMBL3010858 | 0.73 | HPGD (0.36) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL31207928 | 0.73 | SYK (0.40) | MAPTSMN1; SMN2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH IP EE B.V. (NL) | 2010-08-05 | — | — | US | disclosed |
| EP-2167474-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | Valletta Health IP EE B.V. (NL) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153385-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH B.V. (NL) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | UTS2R, UACA, HCAR1 | MAPT 3246/4885SMN1; SMN2 2095/4885ALDH1A1 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.